Patents Examined by Patricia L. Morris
  • Patent number: 10351577
    Abstract: Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: July 16, 2019
    Assignee: Glactone Pharma Development AB
    Inventors: Johansson Martin, Olov Sterner, Anders Bjartell, Rebecka Hellsten, Zilma Escobar
  • Patent number: 10336751
    Abstract: The invention provides novel compounds having the general formula: wherein R1 to R7 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 2, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Chungen Liang, Song Yang
  • Patent number: 10329271
    Abstract: The present disclosure generally relates to methods of preparing nicotine and resolving R,S nicotine to enrich the (S)(?) enantiomer. The method may comprise combining N-methyl-2-pyrrolidone or a salt thereof with a nicotinate compound in the presence of a solvent and a strong base to form 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof; and reducing the 1-methyl-3-nicotinoyl-2-pyrrolidone or salt thereof in solution with Na2S2O4 to produce racemic nicotine or salt thereof. Resolving the racemic nicotine (or other enantiomeric mixture) may comprise combining the nicotine with (?)-O,O?-di-p-toluoyl-L-tartaric acid (L-PTTA).
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 25, 2019
    Assignee: NJOY, LLC
    Inventors: Bert Willis, Mohammed Moinuddin Ahmed, Wesley Freund, Douglas Sawyer
  • Patent number: 10329286
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: June 25, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 10315997
    Abstract: A cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof, wherein the structural formula of the compound is as follows: An application of the compound or its pharmaceutically acceptable salts, hydrates, solvates, or prodrugs in preparing a drug for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes is provided. A drug composition includes the cyclopropyl unsaturated quinoline compound or the pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. The compound series has favorable foreground in preparing the drugs for treating and/or preventing and/or delaying and/or providing adjuvant therapy for asthma and/or allergic rhinitis and asthma syndromes.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: June 11, 2019
    Assignee: GUANGDONG MOLTECH PHARMA CO., LTD.
    Inventor: Yingjie Lai
  • Patent number: 10314831
    Abstract: Small molecule inhibitor compounds for inhibiting Rac1 activity and their use for treating, preventing, or reducing the incidences of malignant and nonmalignant manifestations, e.g., plexiform neurofibromas that occur in subjects suffering from neurofibromatosis type 1 (NF1) are disclosed.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 11, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventor: James H. Wikel
  • Patent number: 10315999
    Abstract: The present application provides processes for making pesticidal compounds and compounds useful both as pesticides and in the making of pesticidal compounds.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 11, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Qiang Yang, Beth Lorsbach, Gregory Whiteker, Gary Roth, Carl DeAmicis, Thomas Clark, Kaitlyn Gray, Belgin Canturk, Elisabeth J. Kane, Yu Zhang, Joseck M. Muhuhi
  • Patent number: 10308630
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10307402
    Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Joerg P. Hehn, Christoph Hoenke, Elke Langkopf
  • Patent number: 10307748
    Abstract: A highly pure optically active proton pump inhibitor compound can be produced safely and inexpensively in a high yield and enantioselectivity by a method of producing an optically active sulfoxide of Formula 2 or a salt thereof, comprising oxidizing a sulfide of Formula 1 or a salt thereof with hydrogen peroxide using an iron salt in the presence of a chiral ligand of Formula 3; wherein A is CH or N; R1 is hydrogen atom, an alkyl optionally substituted by halogen(s), or an alkoxy optionally substituted by halogen(s); one to three R2 may exist, and each of R2 is independently an alkyl, a dialkylamino, or an alkoxy optionally substituted by halogen(s) or alkoxy(s); each of R3 is independently hydrogen atom, a halogen, cyano or the like; R4 is a tertiary alkyl; and * and ** represent respectively R configuration or S configuration.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: June 4, 2019
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Eiichi Nakamura, Laurean Ilies, Yoji Oderaotoshi, Takuhiro Izumi, Shigenobu Nishiguchi
  • Patent number: 10308636
    Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: June 4, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kunio Saruta, Norimitsu Hayashi, Osamu Sakurai, Hiroaki Sawamoto, Eri Ooboki
  • Patent number: 10308659
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier Gavelle, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Roever Stephan, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Patent number: 10308632
    Abstract: Provided are polymorphic forms of compound 5 or 5*, or mixtures thereof, and polymorph forms of compound 14 or 14*, or mixtures thereof. Also provided are methods of preparing compound 5 or 5*, or mixtures thereof, and methods of preparing compound of 14 or 14*, or mixtures thereof, which are useful as antifungal agents. In particular, provided is new methodology for preparing polymorphs of the compounds described and substituted derivatives thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: June 4, 2019
    Assignee: VPS-3, Inc.
    Inventors: David Dale Wirth, Christopher M. Yates
  • Patent number: 10308645
    Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: September 27, 2015
    Date of Patent: June 4, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
  • Patent number: 10301322
    Abstract: The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 28, 2019
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Avedis Karadeolian, Eduardo Gustavo Cammisa, Stuart P. Green, Melanie R. A. Green, Alfredo Paul Ceccarelli
  • Patent number: 10294230
    Abstract: Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 21, 2019
    Assignee: Rugen Holdings (Cayman) Limited
    Inventor: Gideon Shapiro
  • Patent number: 10287275
    Abstract: The invention discloses 20,23-modified novel derivatives of 16-membered demycarosyltylonolide antibiotics, which are useful against bacterial and mycoplasmic pathogens in humans and animals. Also claimed are pharmaceutical compositions of such derivatives and their use in treating bacterial and mycoplasmic infections in humans and animals.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: May 14, 2019
    Assignee: VICTOR PHARMA CO., LTD. ZHENJIANG
    Inventors: Haiqing Yuan, Wenjiang Huang
  • Patent number: 10287282
    Abstract: The present invention provides compounds having the general structural formula (I) [formula should be inserted here] and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving elevated levels of aldosterone or abnormal or excessive fibrosis, such as kidney disease and hypertension.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: May 14, 2019
    Assignee: ANGION BIOMEDICA CORP.
    Inventors: Bijoy Panicker, Lambertus J. W. M. Oehlen
  • Patent number: 10280142
    Abstract: There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 7, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Yoichiro Kuninobu, Motomu Kanai, Haruka Ida, Mitsumi Nishi
  • Patent number: 10273222
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: April 30, 2019
    Assignee: CELGENE QUANTSCEL RESEARCH, INC.
    Inventors: Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal